Creative Medical Technology Holdings, Inc.
CELZHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Creative Medical Technology Holdings, Inc. (CELZ) is listed under Biotechnology. The company carries a $5.6M market cap, placing it firmly in the micro-cap category. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Market Cap
$5.6M
Beta
1.91
P/E (TTM)
—
P/E (Fwd)
-0.84
EPS (TTM)
$-2.07
EPS (Fwd)
$-0.88
ROE
-77.9%
ROA
-47.3%
Cash
$8.8M
Total Debt
$14,194
Free CF
-$3.5M
52W Change
-85.6%
Annual Financials
Cash vs Debt
Where CELZ stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CELZ finished 52.94% below its 150-day moving average ($1.53) and 56.10% below its 200-day moving average ($1.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CELZ overbought or oversold?
At the October 20, 2026 close, CELZ's RSI(14) was 16.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Creative Medical Technology Holdings, Inc. holds $8.8M in cash against $14K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$3.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -77.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $89K (2022) to $6K (2025), a 93% decline worth watching.
Creative Medical Technology Holdings, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CELZ.